Eye Health / Ophthalmic Medical Devices & Pharmaceuticals
Strategic Profile
At its November 2025 investor day, management outlined a three-year transformation plan targeting 5–7% constant currency revenue CAGR through 2028, ~23% adjusted EBITDA margin in 2028, and double-digit adjusted annual EPS growth from 2026–2028. The company projects total peak sales of pipeline products of approximately $7 billion with multiple product launches across Consumer, Pharmaceuticals, Surgical, and Contact Lens businesses spanning 2026–2031.
Cyborg Score Rationale
Bausch Lomb has over 59% chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. However, strong pipeline projections and restructuring initiatives provide growth catalysts, though debt refinancing needs and execution risks remain concerns.
Top Insights
With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
$7 billion in peak pipeline sales projected across multiple therapeutic categories with launches spanning 2026-2031.
The firm was previously a subsidiary under parent company Bausch Health and was spun off to become a public company in 2022.
Refinancing of $2.8 billion term loans anticipated to close in Q1 2026, reducing borrowing costs by 50 basis points.
Named Competitors
Alcon — Comprehensive eye care devices and pharmaceuticals
CIBA Vision — Contact lenses and eye care products
Essilor — Vision correction and optical devices
Recent Developments
(December 2025) Announced refinancing of $2.8 billion term loan tranche at lower rates; closes expected Q1 2026
(November 2025) Investor Day: Unveiled three-year transformation plan with 5-7% revenue CAGR and $7B pipeline peak sales targets
(September 2025) Investment in Character Biosciences as part of innovation strategy
Open the full interactive Bausch + Lomb Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.